Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
1 report, 1 independent
Updated Fri 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup and Cantor Fitzgerald issued rating updates, while disclosures were required by the SEC.
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Cantor Fitzgerald reiterated an overweight rating on CleanSpark shares.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.